Solute Carrier Family 7, Member 5 (SLC7A5) is a member of the SLC family, which can transport large, neutral, and branched-chain amino acids. It is increasingly recognized to play an important role in human cancers. O- (5-Amino-2-phenyl- 7-benzoxazolyl) methyl-3, 5-dichloro-L-tyrosine (JPH203) is a SLC7A5 inhibitor. This study aims to preliminarily explore the potential role of SLC7A5 and the therapeutic effect of JPH203, providing a new direction for cancer treatment. By analyzing data from The Cancer Genome Atlas (TCGA) database and the Gene Type Tissue Expression (GTEx) database, we can elucidate the characteristics of SLC7A5 in cancers, demonstrate the association of SLC7A5 with cancer heterogeneity, and highlight its role in cancer clinical staging. Establish a rat model of hepatocellular carcinoma (HCC) and observe the changes in SLC7A5 after treatment with JPH203. SLC7A5 is highly expressed in most cancers, but has low expression in a few types. Cancers with high expression of SLC7A5 usually have poor prognosis. The mutation rate of SLC7A5 is relatively low and it is closely related to immune system. SLC7A5 is mainly positively correlated with cancer heterogeneity, and in some cancers SLC7A5 is closely related to clinical staging. After treatment with JPH203, the expression of SLC7A5 significantly decreased in HCC. Conclusion: The expression of SLC7A5 varies obviously in different cancers, leading to differential prognosis. It is closely related to immune infiltration and immune cells. JPH203 may play therapeutic role in cancers, suggesting that SLC7A5 may provide new direction and JPH203 may be helpful in the cancer treatment.
Zhang et al. (Mon,) studied this question.